CPhI Online

Cambrex to invest $50 million to expand API manufacturing capacity at Charles City facility

18 Nov 2020

The expansion, which will be operational in early 2022, will increase API manufacturing capacity to meet current customer needs and support growing demand

Cambrex is investing over USD50 million to expand its mid-scale and large-scale active pharmaceutical ingredient (API) manufacturing capacity in Charles City, Iowa to meet growing demand for small molecule drug substance development and manufacturing, the CDMO said Tuesday.

The move is the sixth major investment that Cambrex has made at the site in the past eight years to support customers in mid-scale, large-scale and highly potent small molecule API manufacturing.

The expansion, which will be operational in early 2022, will add three large-scale manufacturing work centres and one mid-scale work centre to the facility, increasing the site’s capacity by 30 percent. When completed, the Charles City site will employ more than 400 people.

“Small molecule manufacturing demand has been growing consistently over recent years, and this investment will enable Cambrex to continue to capitalize on this growth, further strengthening our position as a market-leading CDMO,” said Joe Nettleton, President of Cambrex’s Drug Substance Business Unit. “This expansion in the US for API manufacturing capacity comes at a time when our customers increasingly require high-quality partners to ensure reliable supply chains within the pharmaceutical sector.”

Charles City is located on a 45-acre site, and as part of the company’s Drug Substance business unit, manufactures a wide range of APIs and pharmaceutical intermediates, including highly potent molecules and controlled substances.

In 2019, Cambrex was acquired by funds advised by Permira, a global investment firm, to continue to build upon Cambrex’s strong position in API development and manufacturing and support the growth of its integrated service offering across the pharmaceutical value chain.

Related Categories

Related Content